In Vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration Strategy

VT-1129 is a novel fungal enzyme-specific Cyp51 inhibitor with potent cryptococcal activity. Because of its long half-life (>6 days in mice) and our desire to quickly reach potent efficacy, we evaluated a VT-1129 loading dose-maintenance dose strategy against cryptococcal meningitis. VT-1129 plas...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Wiederhold, Nathan P., Xu, Xin, Wang, Amy, Najvar, Laura K., Garvey, Edward P., Ottinger, Elizabeth A., Alimardanov, Asaf, Cradock, Jim, Behnke, Mark, Hoekstra, William J., Brand, Stephen R., Schotzinger, Robert J., Jaramillo, Rosie, Olivo, Marcos, Kirkpatrick, William R., Patterson, Thomas F.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2018
Matèries:
Experimental Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6201077/
https://ncbi.nlm.nih.gov/pubmed/30104280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01315-18
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars